[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fnND0WdKCro5JQfGAoOvYG1WE7VX1HtuZs2oO3lDUmg4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":10,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"University Of Perugia",[4],53,false,6,10931,0,35,[13,16,19,22,24,26,29,31],{"name":14,"count":15},"Atherosclerosis",5,{"name":17,"count":18},"Pelvic Organ Prolapse",4,{"name":20,"count":21},"Inflammation",3,{"name":23,"count":21},"Pulmonary Embolism",{"name":25,"count":21},"Urinary Incontinence",{"name":27,"count":28},"Venous Thromboembolism",2,{"name":30,"count":28},"Deep Venous Thrombosis",{"name":32,"count":28},"Hypercholesterolemia",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,82,111,137,169,187,205,231,262,288,314,332,356,382,407,433,451,476,502,520,544,574],{"intervention":43,"totalTrials":28,"cells":44},"Intravesical injection of Botulinum A Toxin",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":80},{"trials":46,"activeCount":10},[],{"trials":48,"activeCount":10},[],{"trials":50,"activeCount":10},[],{"trials":52,"activeCount":10},[],{"trials":54,"activeCount":10},[55,66],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":65},"NCT01157507","Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome","UNKNOWN",[39],"2011-09","2010-01",30,[64],"Painful Bladder Syndrome (PBS)",[43],{"nctId":67,"briefTitle":68,"status":58,"phases":69,"primaryCompletion":70,"completion":71,"start":72,"enrollment":73,"conditions":74,"interventions":78},"NCT00822913","Botulinum A Toxin in Patients With Parkinson's Disease",[39],"2008-12","2009-12","2008-06",20,[75,76,77],"Parkinson's Disease","Multiple System Atrophy","Detrusor Overactivity",[79],"Intravesical injection of Botulinum A toxin",{"trials":81,"activeCount":10},[],{"intervention":83,"totalTrials":84,"cells":85},"Maraviroc 300 mg",1,{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":94,"NA":109},{"trials":87,"activeCount":10},[],{"trials":89,"activeCount":10},[],{"trials":91,"activeCount":10},[],{"trials":93,"activeCount":10},[],{"trials":95,"activeCount":10},[96],{"nctId":97,"briefTitle":98,"status":99,"phases":100,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":108},"NCT03402815","Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.","COMPLETED",[39],"2017-04-30","2017-09-30","2015-01-01",22,[106,107,14,20],"HIV Infection With Other Conditions","Cardiovascular Risk Factor",[83],{"trials":110,"activeCount":10},[],{"intervention":112,"totalTrials":84,"cells":113},"4% chlorhexidine gluconate soap-like solution",{"EARLY_PHASE1":114,"PHASE1":116,"PHASE2":118,"PHASE3":120,"PHASE4":122,"NA":135},{"trials":115,"activeCount":10},[],{"trials":117,"activeCount":10},[],{"trials":119,"activeCount":10},[],{"trials":121,"activeCount":10},[],{"trials":123,"activeCount":10},[124],{"nctId":125,"briefTitle":126,"status":99,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},"NCT03639363","4% Chlorhexidine Gluconate Daily Bathing for Prevention of Hospital-acquired Infections in Intensive Care Settings",[39],"2016-04-28","2016-05-02","2015-08-10",449,[133],"Hospital Infection",[112],{"trials":136,"activeCount":10},[],{"intervention":138,"totalTrials":84,"cells":139},"co-ultraPEALut",{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":167},{"trials":141,"activeCount":10},[],{"trials":143,"activeCount":10},[],{"trials":145,"activeCount":10},[],{"trials":147,"activeCount":10},[],{"trials":149,"activeCount":10},[150],{"nctId":151,"briefTitle":152,"status":99,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":164},"NCT04853836","Olfactory Disfunction and Co-ultraPEALut",[39],"2021-10-28","2022-08-31","2020-11-15",200,[159,160,161,162,163],"Anosmia","Covid19","Hyposmia","Parosmia","Treatment Compliance",[138,165,166],"PEA-LUT 1 sachet","PEA-LUT 2 sachet day",{"trials":168,"activeCount":10},[],{"intervention":165,"totalTrials":84,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":185},{"trials":172,"activeCount":10},[],{"trials":174,"activeCount":10},[],{"trials":176,"activeCount":10},[],{"trials":178,"activeCount":10},[],{"trials":180,"activeCount":10},[181],{"nctId":151,"briefTitle":152,"status":99,"phases":182,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":183,"interventions":184},[39],[159,160,161,162,163],[138,165,166],{"trials":186,"activeCount":10},[],{"intervention":166,"totalTrials":84,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":203},{"trials":190,"activeCount":10},[],{"trials":192,"activeCount":10},[],{"trials":194,"activeCount":10},[],{"trials":196,"activeCount":10},[],{"trials":198,"activeCount":10},[199],{"nctId":151,"briefTitle":152,"status":99,"phases":200,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":201,"interventions":202},[39],[159,160,161,162,163],[138,165,166],{"trials":204,"activeCount":10},[],{"intervention":206,"totalTrials":84,"cells":207},"Influenza vaccination",{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":216,"NA":229},{"trials":209,"activeCount":10},[],{"trials":211,"activeCount":10},[],{"trials":213,"activeCount":10},[],{"trials":215,"activeCount":10},[],{"trials":217,"activeCount":10},[218],{"nctId":219,"briefTitle":220,"status":99,"phases":221,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":228},"NCT00222638","Influenza Vaccination and Oral Anticoagulant Therapy",[39],"2005-05","2004-10",100,[226,227],"Anticoagulants","Influenza Vaccines",[206],{"trials":230,"activeCount":10},[],{"intervention":232,"totalTrials":84,"cells":233},"Heparin, Low-Molecular-Weight",{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":258,"NA":260},{"trials":235,"activeCount":10},[],{"trials":237,"activeCount":10},[],{"trials":239,"activeCount":10},[],{"trials":241,"activeCount":10},[242],{"nctId":243,"briefTitle":244,"status":58,"phases":245,"primaryCompletion":246,"start":247,"enrollment":248,"conditions":249,"interventions":257},"NCT01589146","ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.",[38],"2012-12","2010-09",400,[250,251,252,253,254,255,256],"The Primary Study Objective is to Assess the Efficacy and","Safety of Extended 4-week Heparin Prophylaxis Compared to","Prophylaxis Given for 8±2 Days After Planned Laparoscopic","Surgery for Colorectal Cancer.","The Clinical Benefit Will be Evaluated as the Difference in","the Incidence of VTE or VTE-related Death Occurring Within 30 Days","From Surgery in the Two Study Groups.",[232],{"trials":259,"activeCount":10},[],{"trials":261,"activeCount":10},[],{"intervention":263,"totalTrials":84,"cells":264},"Enoxaparin",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":284,"NA":286},{"trials":266,"activeCount":10},[],{"trials":268,"activeCount":10},[],{"trials":270,"activeCount":10},[],{"trials":272,"activeCount":10},[273],{"nctId":274,"briefTitle":275,"status":276,"phases":277,"primaryCompletion":278,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":283},"NCT01573169","PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients","TERMINATED",[38],"2020-03","2012-05",73,[282,27,30],"Hemorrhagic Stroke",[263],{"trials":285,"activeCount":10},[],{"trials":287,"activeCount":10},[],{"intervention":289,"totalTrials":84,"cells":290},"IncobotulinumtoxinA 100 UNT Injection [Xeomin]",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":310,"NA":312},{"trials":292,"activeCount":10},[],{"trials":294,"activeCount":10},[],{"trials":296,"activeCount":10},[],{"trials":298,"activeCount":10},[299],{"nctId":300,"briefTitle":301,"status":58,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},"NCT03758235","Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin",[38],"2021-09-01","2018-09-01",140,[307],"Overactive Bladder Syndrome",[289,309],"OnabotulinumtoxinA 100 UNT [Botox]",{"trials":311,"activeCount":10},[],{"trials":313,"activeCount":10},[],{"intervention":309,"totalTrials":84,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":328,"NA":330},{"trials":317,"activeCount":10},[],{"trials":319,"activeCount":10},[],{"trials":321,"activeCount":10},[],{"trials":323,"activeCount":10},[324],{"nctId":300,"briefTitle":301,"status":58,"phases":325,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":326,"interventions":327},[38],[307],[289,309],{"trials":329,"activeCount":10},[],{"trials":331,"activeCount":10},[],{"intervention":333,"totalTrials":84,"cells":334},"aspirin",{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":352,"NA":354},{"trials":336,"activeCount":10},[],{"trials":338,"activeCount":10},[],{"trials":340,"activeCount":10},[],{"trials":342,"activeCount":10},[343],{"nctId":344,"briefTitle":345,"status":58,"phases":346,"primaryCompletion":347,"start":348,"enrollment":349,"conditions":350,"interventions":351},"NCT00222677","Aspirin for the Prevention of Recurrent Venous Thromboembolism",[37,38],"2012-01","2004-05",70,[27,30,23,14],[333],{"trials":353,"activeCount":10},[],{"trials":355,"activeCount":10},[],{"intervention":357,"totalTrials":84,"cells":358},"prulifloxacin",{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":376,"PHASE4":378,"NA":380},{"trials":360,"activeCount":10},[],{"trials":362,"activeCount":10},[],{"trials":364,"activeCount":10},[365],{"nctId":366,"briefTitle":367,"status":58,"phases":368,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":375},"NCT01231737","Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin)",[37],"2011-02","2012-02","2010-11",96,[374],"Urinary Tract Infection",[357],{"trials":377,"activeCount":10},[],{"trials":379,"activeCount":10},[],{"trials":381,"activeCount":10},[],{"intervention":383,"totalTrials":84,"cells":384},"Thymosin alpha 1",{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":401,"PHASE4":403,"NA":405},{"trials":386,"activeCount":10},[],{"trials":388,"activeCount":10},[],{"trials":390,"activeCount":10},[391],{"nctId":392,"briefTitle":393,"status":58,"phases":394,"primaryCompletion":395,"completion":396,"start":395,"enrollment":397,"conditions":398,"interventions":400},"NCT00580450","Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies",[36,37],"2007-12","2010-12",9,[399],"Hematological Malignancies",[383],{"trials":402,"activeCount":10},[],{"trials":404,"activeCount":10},[],{"trials":406,"activeCount":10},[],{"intervention":408,"totalTrials":84,"cells":409},"BCG",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":411,"activeCount":10},[],{"trials":413,"activeCount":10},[],{"trials":415,"activeCount":10},[416],{"nctId":417,"briefTitle":418,"status":99,"phases":419,"primaryCompletion":420,"start":421,"enrollment":422,"conditions":423,"interventions":425},"NCT00696579","Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer",[36,37],"2008-03","2004-01",64,[424],"Bladder Cancer",[408,426],"gemcitabine",{"trials":428,"activeCount":10},[],{"trials":430,"activeCount":10},[],{"trials":432,"activeCount":10},[],{"intervention":426,"totalTrials":84,"cells":434},{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":445,"PHASE4":447,"NA":449},{"trials":436,"activeCount":10},[],{"trials":438,"activeCount":10},[],{"trials":440,"activeCount":10},[441],{"nctId":417,"briefTitle":418,"status":99,"phases":442,"primaryCompletion":420,"start":421,"enrollment":422,"conditions":443,"interventions":444},[36,37],[424],[408,426],{"trials":446,"activeCount":10},[],{"trials":448,"activeCount":10},[],{"trials":450,"activeCount":10},[],{"intervention":452,"totalTrials":84,"cells":453},"Colchicine 1 MG Oral",{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":455,"activeCount":10},[],{"trials":457,"activeCount":10},[],{"trials":459,"activeCount":10},[460],{"nctId":461,"briefTitle":462,"status":276,"phases":463,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":467,"interventions":469},"NCT04375202","Colchicine in COVID-19: a Pilot Study",[37],"2021-10-31","2020-04-18",227,[468],"COVID-19",[452],{"trials":471,"activeCount":10},[],{"trials":473,"activeCount":10},[],{"trials":475,"activeCount":10},[],{"intervention":477,"totalTrials":84,"cells":478},"rFVIIa +",{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":496,"PHASE4":498,"NA":500},{"trials":480,"activeCount":10},[],{"trials":482,"activeCount":10},[],{"trials":484,"activeCount":10},[485],{"nctId":486,"briefTitle":487,"status":58,"phases":488,"completion":489,"start":490,"enrollment":491,"conditions":492,"interventions":494},"NCT00222625","rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets",[37],"2006-09","2005-09",32,[493],"Intracerebral Hemorrhage",[477,495],"FFP or aPCC+ vit K in AO treated patients",{"trials":497,"activeCount":10},[],{"trials":499,"activeCount":10},[],{"trials":501,"activeCount":10},[],{"intervention":495,"totalTrials":84,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":514,"PHASE4":516,"NA":518},{"trials":505,"activeCount":10},[],{"trials":507,"activeCount":10},[],{"trials":509,"activeCount":10},[510],{"nctId":486,"briefTitle":487,"status":58,"phases":511,"completion":489,"start":490,"enrollment":491,"conditions":512,"interventions":513},[37],[493],[477,495],{"trials":515,"activeCount":10},[],{"trials":517,"activeCount":10},[],{"trials":519,"activeCount":10},[],{"intervention":521,"totalTrials":84,"cells":522},"tenecteplase",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":538,"PHASE4":540,"NA":542},{"trials":524,"activeCount":10},[],{"trials":526,"activeCount":10},[],{"trials":528,"activeCount":10},[529],{"nctId":530,"briefTitle":531,"status":276,"phases":532,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":537},"NCT00222651","Tenecteplase Pulmonary Embolism Italian Study",[37],"2006-07","2004-07",180,[23],[521],{"trials":539,"activeCount":10},[],{"trials":541,"activeCount":10},[],{"trials":543,"activeCount":10},[],{"intervention":545,"totalTrials":84,"cells":546},"High dose irradiation conditioning + Treg\u002FTcon",{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":568,"PHASE4":570,"NA":572},{"trials":548,"activeCount":10},[],{"trials":550,"activeCount":10},[],{"trials":552,"activeCount":10},[553],{"nctId":554,"briefTitle":555,"status":58,"phases":556,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":567},"NCT03977103","Irradiation-based Myeloablative Conditioning Followed by Treg\u002FTcon Immunotherapy in HSCT",[37],"2023-02-28","2014-02",80,[561,562,563,564,565,566],"Acute Myeloid Leukemia","Acute Lymphoid Leukemia","Myeloproliferative Disorders","Lymphoma","Multiple Myeloma","Other Hematologic Malignant Neoplasms",[545],{"trials":569,"activeCount":10},[],{"trials":571,"activeCount":10},[],{"trials":573,"activeCount":10},[],{"intervention":575,"totalTrials":84,"cells":576},"Resveratrol",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":585,"NA":587},{"trials":578,"activeCount":10},[],{"trials":580,"activeCount":10},[],{"trials":582,"activeCount":10},[],{"trials":584,"activeCount":10},[],{"trials":586,"activeCount":10},[],{"trials":588,"activeCount":10},[589],{"nctId":590,"briefTitle":591,"status":99,"phases":592,"primaryCompletion":593,"completion":594,"start":595,"enrollment":596,"conditions":597,"interventions":600},"NCT04689412","Nasal Resveratrol and Wheezing Episodes in Preschool Children",[],"2019-03-31","2019-04-30","2018-04-01",50,[598,599],"Wheezing","Upper Respiratory Tract Infections",[575]]